WO2001008669A3 - Therapeutic agents for lymphoedema - Google Patents
Therapeutic agents for lymphoedema Download PDFInfo
- Publication number
- WO2001008669A3 WO2001008669A3 PCT/GB2000/002950 GB0002950W WO0108669A3 WO 2001008669 A3 WO2001008669 A3 WO 2001008669A3 GB 0002950 W GB0002950 W GB 0002950W WO 0108669 A3 WO0108669 A3 WO 0108669A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lymphoedema
- therapeutic agents
- treatment
- flk
- kdr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU63023/00A AU6302300A (en) | 1999-07-30 | 2000-07-31 | Therapeutic agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9918057.2A GB9918057D0 (en) | 1999-07-30 | 1999-07-30 | Therapeutic agents |
GB9918057.2 | 1999-07-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001008669A2 WO2001008669A2 (en) | 2001-02-08 |
WO2001008669A3 true WO2001008669A3 (en) | 2002-07-11 |
Family
ID=10858334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/002950 WO2001008669A2 (en) | 1999-07-30 | 2000-07-31 | Therapeutic agents for lymphoedema |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6302300A (en) |
GB (1) | GB9918057D0 (en) |
WO (1) | WO2001008669A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0409686A (en) | 2003-04-24 | 2006-07-04 | Incyte Corp | aza spiro alkane derivatives as metalloprotease inhibitors |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992014748A1 (en) * | 1991-02-22 | 1992-09-03 | American Cyanamid Company | Identification of a novel human receptor tyrosine kinase gene |
WO1994011499A1 (en) * | 1992-11-13 | 1994-05-26 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Flk-1 is a receptor for vascular endothelial growth factor |
WO1995021613A1 (en) * | 1994-02-09 | 1995-08-17 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
WO1996040648A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
WO1996040629A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders |
WO1996040675A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Thienyl compounds for inhibition of cell proliferative disorders |
WO1997009427A1 (en) * | 1995-09-08 | 1997-03-13 | Genentech, Inc. | Vegf-related protein |
US5650415A (en) * | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
WO1997034920A1 (en) * | 1996-03-21 | 1997-09-25 | Sugen, Inc. | Assays for kdr/flk-1 receptor tyrosine kinase inhibitors |
US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5763441A (en) * | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5766863A (en) * | 1993-11-23 | 1998-06-16 | Genentech, Inc. | Kinase receptor activation assay |
US5766860A (en) * | 1992-11-23 | 1998-06-16 | American Cyanamid Company | Screening method using a recombinant kinase insert domain containing receptor and gene encoding same |
US5773459A (en) * | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
WO1998039035A1 (en) * | 1997-03-07 | 1998-09-11 | The Wistar Institute Of Anatomy & Biology | Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue |
WO1998055638A1 (en) * | 1997-06-03 | 1998-12-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof |
WO1998058053A1 (en) * | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | Human receptor tyrosine kinase, kdr |
WO1999010537A1 (en) * | 1997-08-26 | 1999-03-04 | Board Of Regents, The University Of Texas System | A tumor suppressor designated ts10q23.3 |
US5891650A (en) * | 1993-11-23 | 1999-04-06 | Genentech Incorporated | Kinase receptor activation assay |
WO1999017769A1 (en) * | 1997-10-06 | 1999-04-15 | Basf Aktiengesellschaft | INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES |
WO1999021859A1 (en) * | 1997-10-10 | 1999-05-06 | Glaxo Group Limited | Azaoxindole derivatives |
WO1999024440A1 (en) * | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
US5916763A (en) * | 1995-11-09 | 1999-06-29 | The Regents Of The University Of California | Promoter for VEGF receptor |
WO2000058511A1 (en) * | 1999-03-26 | 2000-10-05 | Ludwig Institute For Cancer Research | Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3) |
-
1999
- 1999-07-30 GB GBGB9918057.2A patent/GB9918057D0/en not_active Ceased
-
2000
- 2000-07-31 WO PCT/GB2000/002950 patent/WO2001008669A2/en active Application Filing
- 2000-07-31 AU AU63023/00A patent/AU6302300A/en not_active Abandoned
Patent Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992014748A1 (en) * | 1991-02-22 | 1992-09-03 | American Cyanamid Company | Identification of a novel human receptor tyrosine kinase gene |
US5861301A (en) * | 1992-02-20 | 1999-01-19 | American Cayanamid Company | Recombinant kinase insert domain containing receptor and gene encoding same |
US5763441A (en) * | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
WO1994011499A1 (en) * | 1992-11-13 | 1994-05-26 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Flk-1 is a receptor for vascular endothelial growth factor |
US5849742A (en) * | 1992-11-13 | 1998-12-15 | Sugen Inc. | Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis |
US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5766860A (en) * | 1992-11-23 | 1998-06-16 | American Cyanamid Company | Screening method using a recombinant kinase insert domain containing receptor and gene encoding same |
US5891650A (en) * | 1993-11-23 | 1999-04-06 | Genentech Incorporated | Kinase receptor activation assay |
US5766863A (en) * | 1993-11-23 | 1998-06-16 | Genentech, Inc. | Kinase receptor activation assay |
WO1995021613A1 (en) * | 1994-02-09 | 1995-08-17 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5773459A (en) * | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
WO1996040648A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
US5710173A (en) * | 1995-06-07 | 1998-01-20 | Sugen, Inc. | Thienyl compounds for inhibition of cell proliferative disorders |
US5650415A (en) * | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
US5891917A (en) * | 1995-06-07 | 1999-04-06 | Sugen, Inc. | Certain acrylonitrile-sulfonamide derivatives |
US5886195A (en) * | 1995-06-07 | 1999-03-23 | Sugen, Inc. | Thienyl compounds for inhibition of cell proliferative disorders |
WO1996040629A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders |
WO1996040675A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Thienyl compounds for inhibition of cell proliferative disorders |
WO1997009427A1 (en) * | 1995-09-08 | 1997-03-13 | Genentech, Inc. | Vegf-related protein |
US5916763A (en) * | 1995-11-09 | 1999-06-29 | The Regents Of The University Of California | Promoter for VEGF receptor |
WO1997034920A1 (en) * | 1996-03-21 | 1997-09-25 | Sugen, Inc. | Assays for kdr/flk-1 receptor tyrosine kinase inhibitors |
WO1998039035A1 (en) * | 1997-03-07 | 1998-09-11 | The Wistar Institute Of Anatomy & Biology | Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue |
WO1998055638A1 (en) * | 1997-06-03 | 1998-12-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof |
WO1998058053A1 (en) * | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | Human receptor tyrosine kinase, kdr |
WO1999010537A1 (en) * | 1997-08-26 | 1999-03-04 | Board Of Regents, The University Of Texas System | A tumor suppressor designated ts10q23.3 |
WO1999017769A1 (en) * | 1997-10-06 | 1999-04-15 | Basf Aktiengesellschaft | INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES |
WO1999021859A1 (en) * | 1997-10-10 | 1999-05-06 | Glaxo Group Limited | Azaoxindole derivatives |
WO1999024440A1 (en) * | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
WO2000058511A1 (en) * | 1999-03-26 | 2000-10-05 | Ludwig Institute For Cancer Research | Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3) |
Non-Patent Citations (6)
Title |
---|
M.H.WITTE ET AL.: "PHENOTYPIC AND GENOTYPIC HETEROGENEITY IN FAMILIAL MILROY LYMPHEDEMA", LYMPHOLOGY, vol. 31, no. 4, December 1998 (1998-12-01), pages 145 - 155, XP000990600 * |
M.J.KARKKAINEN ET AL.: "Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis", ONCOGENE, vol. 19, no. 49, 20 November 2000 (2000-11-20), pages 5598 - 5605, XP000990610 * |
R.E.FERRELL ET AL.: "Hereditary lymphedema: evidence for linkage and genetic heterogeneity", HUMAN MOLECULAR GENETICS, vol. 7, no. 13, December 1998 (1998-12-01), pages 2073 - 2078, XP000990647 * |
T. MÄKINEN ET AL.: "Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3", NAT.MED., vol. 7, no. 2, February 2001 (2001-02-01), pages 199 - 205, XP000990590 * |
V. JOUKOV ET AL.: "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases", THE EMBO JOURNAL, vol. 15, no. 2, 1996, pages 290 - 298, XP000100201 * |
Y. CAO ET AL.: "Vascular endothelial growth factor C induces angiogenesis in vivo", PROC.NATL.ACAD.SCI. USA, vol. 95, no. 24, 24 November 1998 (1998-11-24), pages 14389 - 14394, XP000994696 * |
Also Published As
Publication number | Publication date |
---|---|
AU6302300A (en) | 2001-02-19 |
WO2001008669A2 (en) | 2001-02-08 |
GB9918057D0 (en) | 1999-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL135712A0 (en) | Methods for treating hypercoagulable states or acquired protein c deficiency | |
SE9702860D0 (en) | New use | |
WO2002058696A3 (en) | The use of substituted azetidinone compounds for the treatment of sitosterolemia | |
HK1130422A1 (en) | A new use of deferiprone | |
DE69116380T2 (en) | PHARMACEUTICAL PREPARATION FOR TREATING EXTENDED COAGLING TIME | |
WO2001024783A3 (en) | Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence | |
GB0020504D0 (en) | Therapeutic method | |
MY140626A (en) | Drug screening methods and method of treatment | |
WO2001008669A3 (en) | Therapeutic agents for lymphoedema | |
SE9101840D0 (en) | NEW MEDICINAL USE | |
PL354961A1 (en) | Prevention and treatment of diseases associated with blood coagulation | |
WO2003001877A3 (en) | Methods for the diagnosis and treatment of cardiac tissue rejection | |
IL150541A0 (en) | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith | |
AU2003283227A8 (en) | Method and means for the treatment of vascular and cardiac diseases | |
NO995459D0 (en) | Tissue factor for influencing blood vessel formation | |
WO2001022976A3 (en) | Combination of a statin and ex-vivo treated blood for treating artheroclerosis | |
BR0316059A (en) | Use of fosinopril to reduce cardiovascular events in dialysis patients | |
AU2002225994A1 (en) | Use of blood coagulation factor xiii for treating haemophilia | |
Neutel et al. | P-373: A comparison of the effects of amlodipine 5 mg/benazepril 20 mg combination therapy to component monotherapy on arterial distensibilitly and left ventricular hypertrophy in patients with mild to moderate hypertension | |
DE60122781D1 (en) | NEW THERAPEUTIC USE OF A DERIVATIVE OF THIENYLCYCLOHEXYLAMINE FOR THE TREATMENT OF PAIN | |
EP1714661A3 (en) | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity | |
KR20200089899A (en) | Easy to attach waterproof mediband | |
Beckles et al. | P-375: Attenuation of cardiac hypertrophy in vivo by interference with the jak/Stat pathway | |
WO2000050023A3 (en) | Use of tamoxifen and related compounds as CLC3 blockers in the treatment of vascular diseases | |
SI1239873T1 (en) | Use of fibrinolytic metalloproteinases for the therapeutic treatment of a blood clot |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |